Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Anil P Bidkar *Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1249-1081
Robin Peter *Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0009-0003-3448-8462
Anju WadhwaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0009-0006-0826-8134
Kondapa Naidu BobbaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-6304-2855
Scott BidlingmaierDepartment of Anesthesia, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4955-9713
Niranjan MeherDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3558-3712
Jonathan ChouDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1258-0391
Nancy GreenlandDepartment of Pathology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1783-1711
Chandrashekhar DasariDivision of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-7526-2190
Athira RaveendranDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4853-4330
Megha BasakDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2422-184X
Juan Antonio Camara SerranoUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.ORCID 0000-0001-7494-1127
Veronica SteriUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.ORCID 0000-0003-2499-6618
Scott KoganDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2395-8479
Adam OskowitzDivision of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-7213-0555
Jiang HeDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia.ORCID 0000-0001-7600-4604
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1095-046X
Rahul AggarwalDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-7003-7982
Renuka SriramDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3505-2479
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-2849-0841
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5908-6636
Bin LiuDepartment of Anesthesia, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-9137-5067
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8694-1199
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerR01CA223767 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG, LIU, BIN · 2018 to 2022
$2.8M
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapyR01CA279203 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Robert Richard Flavell, Youngho Seo · 2023 to 2026
$2.6M
Energy-independent single photon molecular imaging technologyR01EB026331 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CUI, YONGGANG, SEO, YOUNGHO · 2018 to 2022
$2.6M
Mapping a clinically significant internalizing tumor epitope space.R01CA118919 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, BIN · 2006 to 2013
$2.5M
High-throughput microPET/CT at UCSF Preclinical Imaging CoreS10OD034286 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2023 to 2023
$662k
All of Us Research Program (AoURP) S10OD034286DOD Prostate Cancer Research Program (PCRP) HT9425-23-1-0139DOD Prostate Cancer Research Program (PCRP) W81XWH-20-1-0292DOD Prostate Cancer Research Program (PCRP) W81XWH-21-1-0792National Cancer Institute (NCI) R01CA279203National Institute of Biomedical Imaging and Bioengineering (NIBIB) R01CA223767NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA118919NCI NIH HHS R01 CA223767NCI NIH HHS R01 CA279203NIBIB NIH HHS R01 EB026331NIH HHS S10 OD034286U.S. Department of Defense (DOD) W81XWH-20-1-0136
6 · The paper itself
Abstract
purposeMetastatic castration-resistant prostate cancer has limited treatment options and a poor prognosis. Recently, prostate-specific membrane antigen (PSMA)-targeted alpha-particle therapy agents using actinium-225 (225Ac) have shown promising results in prostate cancer treatment, but a significant fraction of patients with advanced mCRPC demonstrate loss of PSMA expression. We have previously reported that PSMA-null and PSMA-positive tumors can be detected and treated effectively with CD46-targeted radiopharmaceuticals. This study evaluates the CD46-targeting PET imaging agent [89Zr]DFO-YS5, and the radioimmunotherapy agent [225Ac]Macropa-PEG4-YS5, in disseminated prostate cancer tumors. EXPERIMENTAL
designMicrotumor lesions, primarily observed in the liver, kidneys, and lungs, were successfully detected with [89Zr]DFO-YS5 PET imaging. We used disseminated 22Rv1 tumors for biodistribution studies, dosimetry assessments, and therapeutic efficacy evaluations of [225Ac]Macropa-PEG4-YS5.
resultsQuantitative digital alpha-particle autoradiography revealed high radiation dose deposition from [225Ac]Macropa-PEG4-YS5 in microtumors compared with surrounding liver tissues, although in larger lesions (>1 mm diameter), the dose distribution was heterogeneous. Early treatment of smaller disseminated tumors with a uniform radiation dose was more effective in ablating tumors and promoting survival. In late-stage lesions of large size, heterogeneous dose deposition limited therapeutic efficacy, requiring higher administered activity to achieve a complete response.
conclusionsOur findings highlight that [225Ac]Macropa-PEG4-YS5 holds the potential for clinical translation for metastatic prostate cancer and reinforces the value of microdosimetry in understanding the efficacy of and resistance to targeted alpha therapy. See related commentary by Patel et al., p. 2847.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. · full record | OpenQuestion